Oklo
OKLO
$39.88
-6.32%
Oklo Inc. is a nuclear technology company developing advanced fission power plants, specifically its Aurora powerhouse line of liquid metal fast reactors, to provide clean, reliable, and affordable energy at scale, alongside used nuclear fuel recycling services. As a pre-revenue player in the emerging small modular reactor (SMR) industry, Oklo distinguishes itself through its innovative reactor design and its focus on fuel recycling, positioning it as a potential disruptor in the nuclear energy sector. The current investor narrative centers on Oklo's strategic partnerships, including a landmark deal with Meta to supply 1.2 gigawatts of power, and its inclusion in the U.S. government's 'Project Prometheus' initiative, which have fueled optimism about its long-term growth prospects despite the company being in its early development stage. However, the stock's significant volatility and the speculative nature of its unproven technology and regulatory pathway remain key points of debate among investors.…
OKLO
Oklo
$39.88
Related headlines
Investment Opinion: Should I buy OKLO Today?
Rating: Hold. Oklo is a speculative pre-revenue company with a promising technology but unproven execution. The average analyst target of $79.875 implies 93.5% upside, but the wide range ($14-$130) and lack of consensus (recommendation 'none') reflect high uncertainty. The thesis is that Oklo's strategic partnerships and government support could drive long-term value, but the current valuation and cash burn make it a high-risk bet.
Sign up to view all
OKLO 12-Month Price Forecast
Oklo's forward-looking view is balanced. The company has significant potential given the Meta deal and government support, but the lack of revenue and extreme valuation create substantial risk. The stock's 78.84% drawdown suggests the market is already pricing in many challenges, but further downside is possible if execution falters. I would upgrade to bullish if Oklo announces a second major customer or achieves regulatory milestones, and downgrade to bearish if the company announces a dilutive offering or misses key deadlines.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oklo's 12-month outlook, with a consensus price target around $79.88 and implied upside of +100.3% versus the current price.
Average Target
$79.88
0 analysts
Implied Upside
+100.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $130
Analyst target range
Oklo is covered by 20 analysts, with a consensus recommendation of 'none' and an average target price of $79.875, implying an upside of approximately 93.5% from the current price of $41.27. The analyst sentiment appears mixed, with recent actions from firms like UBS and Citigroup maintaining Neutral ratings, while Wedbush and Cantor Fitzgerald have Outperform/Overweight ratings, indicating a lack of strong consensus. The target price range is wide, from a low of $14.00 to a high of $130.00, reflecting high uncertainty about the company's future prospects, with the low target suggesting potential downside of -66% and the high target implying a potential upside of 215%.
Bulls vs Bears: OKLO Investment Factors
Oklo presents a high-risk, high-reward speculative investment. The bull case rests on transformative partnerships (Meta), government backing (Project Prometheus), and a clean balance sheet, while the bear case is dominated by a complete lack of revenue, escalating losses, and an extreme valuation that prices in flawless execution. Currently, bearish evidence is stronger given the stock's 78.84% drawdown and negative technical momentum, but the potential upside to analyst targets is substantial. The central tension is whether Oklo can navigate regulatory and technical challenges to deliver on its commercial promises before its cash reserves run out, as any delay could trigger a further de-rating toward the $14 low target.
Bullish
- Meta Deal Validates Technology: Oklo's landmark agreement to supply Meta with 1.2 gigawatts of power is a major commercial validation, signaling demand from a top-tier tech company. This deal, announced in 2026, provides a tangible revenue path and underscores the market's need for clean, reliable nuclear energy to power AI data centers.
- Government Support via Project Prometheus: Oklo's inclusion in the U.S. government's 'Project Prometheus' initiative, alongside X-Energy and Standard Nuclear, highlights strong federal backing for its technology. This support, which excludes competitor NuScale, could accelerate regulatory approvals and provide funding opportunities, de-risking the development pathway.
- Strong Balance Sheet with Minimal Debt: Oklo maintains a debt-to-equity ratio of 0.001, indicating virtually no debt, and a current ratio of 49.08, reflecting ample liquidity to fund operations. This financial cushion supports the company through its pre-revenue phase without immediate solvency concerns.
- Analyst Targets Imply Significant Upside: The average analyst target price of $79.875 implies a 93.5% upside from the current price of $41.27, with the high target of $130 suggesting a 215% potential gain. This optimism reflects the market's belief in Oklo's long-term growth prospects despite current losses.
Bearish
- Pre-Revenue with Widening Losses: Oklo reported zero revenue in Q1 2026, with net losses widening to -$33.06 million from -$9.81 million in Q1 2025, a 237% increase. Operating expenses surged to $51.25 million, reflecting heavy R&D and G&A spending, with no offsetting income, indicating a prolonged cash burn phase.
- Extreme Valuation with No Earnings: With zero revenue, the EV/Sales ratio is a meaningless 4090.85x, and the trailing PE is -99.67x. The price-to-book ratio of 7.11x suggests investors are paying a premium for cash and assets, but the lack of revenue makes traditional valuation metrics unreliable and signals speculative pricing.
- Massive Drawdown and Downtrend: The stock has fallen 78.84% from its 52-week high of $193.84 to $41.27, and is down 40.71% over the past year. Trading near the lower end of its 52-week range (21% of the range), the technical trend is bearish, with persistent selling pressure and negative relative strength versus the S&P 500.
- Regulatory and Technical Hurdles: Oklo's SMR technology is unproven at commercial scale, and the Meta deal's 2030 timeline is considered optimistic given regulatory hurdles. The Nuclear Regulatory Commission's approval process is lengthy and uncertain, and any delays could push revenue generation further out, undermining the current valuation.
OKLO Technical Analysis
Oklo's stock is in a pronounced downtrend, with a 1-year price change of -40.71% and a current price of $41.27, which is near the lower end of its 52-week range (between $36.61 and $193.84). The stock is trading at approximately 21% of its 52-week range, indicating it is closer to its lows than its highs, which suggests bearish sentiment and potential value trap dynamics. The stock has experienced a massive drawdown of -78.84% from its peak, reflecting a significant loss of investor confidence and a persistent selling pressure over the past year.
Beta
1.20
1.20x market volatility
Max Drawdown
-78.8%
Largest decline past year
52-Week Range
$37-$194
Price range past year
Annual Return
-45.9%
Cumulative gain past year
| Period | OKLO Return | S&P 500 |
|---|---|---|
| 1m | -15.2% | -1.6% |
| 3m | -30.6% | +2.2% |
| 6m | -31.7% | +14.4% |
| 1y | -45.9% | +16.2% |
| ytd | -48.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OKLO Fundamental Analysis
Oklo is a pre-revenue company, with zero revenue reported in the most recent quarter (Q1 2026) and consistently no revenue over the past several quarters, indicating it is still in the development phase with no commercial operations. The company's net loss widened to -$33.06 million in Q1 2026 from -$9.81 million in Q1 2025, reflecting increased investment in research and development (R&D) and general administrative expenses as it scales up its operations. The gross margin is negative at -$0.163 million in Q1 2026, as the company incurs costs without corresponding revenue, and operating margins are deeply negative, with operating income of -$51.25 million in Q1 2026, highlighting the significant cash burn typical of early-stage nuclear technology companies.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-153481000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OKLO Overvalued?
Given that Oklo has negative net income and negative EBITDA, the most appropriate valuation metric is the EV/Sales ratio, which is 4090.85x based on zero revenue, making it essentially meaningless and reflecting the market's speculative pricing of future potential. The trailing PE ratio is -99.67x, and the forward PE is -41.10x, both negative, indicating that the company is not expected to be profitable in the near term. The price-to-book ratio of 7.11x suggests that investors are paying a premium for the company's book value, which is primarily cash and investments, but the lack of revenue and earnings makes traditional valuation metrics unreliable.
PE
-99.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-88.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are severe: Oklo has no revenue and burned $33.06 million in Q1 2026, with operating expenses of $51.25 million. The company's negative free cash flow of -$153.48 million TTM and reliance on cash reserves (current ratio 49.08) mean it will likely need to raise capital, causing dilution. The widening net loss from -$9.81 million to -$33.06 million year-over-year indicates accelerating cash burn, and with no clear path to profitability, the company is vulnerable to funding gaps if market conditions deteriorate.
FAQ
The key risks are: (1) Financial risk: cash burn of -$153.48 million TTM and widening losses, which may require dilutive capital raises; (2) Regulatory risk: NRC approval is uncertain and could be delayed, pushing revenue to 2030 or later; (3) Competitive risk: NuScale and other SMR developers may capture market share; (4) Market risk: the stock's high beta of 1.195 and 78.84% drawdown highlight its volatility. The most severe risk is a failure to secure regulatory approval, which could lead to a 66% downside to the $14 target.
The 12-month forecast is uncertain, with three scenarios: Bull case (25% probability) targets $80-$130, driven by regulatory progress and new deals; Base case (50% probability) targets $50-$80, assuming steady but slow progress; Bear case (25% probability) targets $14-$40, if regulatory or technical issues arise. The most likely scenario is the base case, with the stock trading around the analyst average of $79.875, but the wide range reflects high uncertainty. Key assumptions include the Meta deal staying on track and no major regulatory setbacks.
Oklo is significantly overvalued based on traditional metrics, with an EV/Sales ratio of 4090.85x and a price-to-book of 7.11x, despite having zero revenue. The market is pricing in massive future growth, implying that Oklo will successfully commercialize its technology and generate substantial revenue. Compared to peers, Oklo trades at a premium, but the lack of earnings makes valuation comparisons difficult. The stock is undervalued only if you believe the company will achieve its ambitious targets, which is a high-risk assumption.
Oklo is not a good buy for risk-averse investors due to its pre-revenue status and extreme valuation. However, for speculative investors with a high risk tolerance, the stock offers significant upside potential, with analyst targets implying 93.5% upside. The biggest downside risk is a drop to the $14 low target, representing a 66% loss. It could be a good buy if you believe in the nuclear energy renaissance and are willing to withstand high volatility, but only as a small position in a diversified portfolio.
Oklo is more suitable for long-term investment (5+ years) due to its early-stage nature and the long timeline to commercialization. The stock is highly volatile, with a beta of 1.195 and a 78.84% drawdown, making it risky for short-term trading. The company has no revenue or dividends, so returns depend entirely on capital appreciation. Investors should be prepared for significant price swings and hold through the development phase, as the technology's success will only be known in the long term. A minimum holding period of 5 years is recommended to allow for regulatory approvals and commercial deployment.